BIONTECH SE diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit https://www.globenewswire.com/Tracker?data=IdI-qbe4Qm6dyU_Q_5Bj39npl0tTXSV_xDV1GffUhe9JgJGYX9YHSRRhSPxujLZdYjBP6PZuc39-TCLe50I4DQ== www.BioNTech.de Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including BioNTech's expected revenues and net profit related to sales of BioNTech and Pfizer's COVID-19 vaccine, referred to as COMIRNATY(R) in the European Union as authorized for use under conditional marketing approval, in territories controlled by BioNTech's collaboration partners, particularly those such figures that are derived from preliminary estimates provided by BioNTech's partners; the extent to which a COVID-19 vaccine continues to be necessary in the future; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the pricing and reimbursement of BioNTech and Pfizer's COVID-19 vaccine and BioNTech's investigational medicines, if approved; the rate and degree of market acceptance of BioNTech and Pfizer's COVID-19 vaccine and BioNTech's investigational medicines, if approved; the initiation, timing, progress, results, and cost of BioNTech's research and development programs and BioNTech's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and BioNTech's research and development programs; the timing of and BioNTech's ability to obtain and maintain regulatory approval for BioNTech's product candidates; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of BioNTech and Pfizer's COVID-19 vaccine, and other products and product candidates developed or manufactured by BioNTech; BioNTech's estimates of its expenses, ongoing losses, future revenue and capital requirements and BioNTech's needs for or ability to obtain additional financing; the development of and projections relating to BioNTech's competitors or its industry; BioNTech's ability to effectively scale its production capabilities and manufacture its products, including BioNTech and Pfizer's COVID-19 vaccine, and BioNTech's product candidates; BioNTech's projected net sales for the COVID-19 vaccine in 2021; BioNTech's projected gross margins, expenses and expenditures and tax rate for 2021; BioNTech's target vaccine production for 2021; and BioNTech's COVID-19 vaccine revenues and net sales, which are subject to numerous estimates as more fully described in our Annual Report on Form 20-F. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Annual Report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on March 31, 2020 and in subsequent filings made by BioNTech with the SEC, including the third quarter report, which are available on the SEC's website at https://www.globenewswire.com/Tracker?data=IdI-qbe4Qm6dyU_Q_5Bj3wP2E4ZRvPUjyQAettaL0wlatDplbiqTeQ05JIJiv37gOEg5cy0Lbe0hJw2Jg9LjHA== www.sec.gov. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof. Investor Relations Sylke Maas, Ph.D. VP Investor Relations & Strategy Tel: +49 (0)6131 9084 1074 E-mail: https://www.globenewswire.com/Tracker?data=LzsmZe_1DG9QNNJgxuuFDo0yVIk1WGV-0VYTTyXwe5wjPIOmFcqcX_Y_arqGJnbGywLrKNR8i9wEMyN8vCJEliLOXGTlkV1fIjASLsQtLRCugEitVE0vztnjB3Pt7yoYmrid90y_hqY-1WdktbWJKQeHLCUzC1TFv5B51jLv7MBaRDcz6-_cVp4S0De6dkmot5wtsyEUXZZ6NO6Y-7xuK7BMRGLOgx9MQa6v2eRMnbEwxWOP_BIkmUvzLkF5_Lm7JuURJQPVMHGjtIfTWVsXWA== Investors@biontech.de Media Relations Jasmina Alatovic Director Global External Communications Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 E-mail: Media@biontech.de https://www.globenewswire.com/Tracker?data=10WoDOYeMBjy5XjG7dMt_-rb553S9rtGczWmwU17X4mKFk0DAqMw5v_69zQeUPm3vQAqf0E4znymC_B2I0_DinU3jNVPxVcPvxE1BFWfdfg= Consolidated Statements of Financial Position December 31, December 31, (in thousands) 2020 2019 Assets -------------------------------------- ------------- Non-current assets Intangible assets EUR 163,490 EUR 89,434 Property, plant and equipment 226,968 93,044 Right-of-use assets 98,988 55,018 Other assets 1,045 - Deferred tax assets 161,233 - Total non-current assets EUR 651,724 EUR 237,496 -------------------------------------- ------------- ------------ Current assets Inventories 64,120 11,722 Trade receivables 165,468 11,913 Other financial assets 137,234 1,680 Other assets 60,966 9,069 Income tax assets 898 756 Deferred expenses 28,001 5,862 Cash and cash equivalents 1,210,209 519,149 Total current assets EUR 1,666,896 EUR 560,151 -------------------------------------- ------------- ------------ Total assets EUR 2,318,620 EUR 797,647 -------------------------------------- ------------- Equity and liabilities -------------------------------------- ------------- Equity Share capital 246,310 232,304 Capital reserve 1,514,451 686,714 Treasury shares (4,789) (5,525) Accumulated losses (409,629) (424,827) Other reserves 25,503 4,826 Total equity EUR 1,371,846 EUR 493,492 -------------------------------------- ------------- ------------ Non-current liabilities Interest-bearing loans and borrowings 231,047 68,904 Other financial liabilities 31,476 - Provisions 5,498 - Contract liabilities 71,892 97,109 Other liabilities 566 - Deferred tax liabilities 281 - Total non-current liabilities EUR 340,760 EUR 166,013 -------------------------------------- ------------- ------------ Current liabilities Interest-bearing loans and borrowings 9,142 5,307 Trade payables 102,288 20,498 Other financial liabilities 74,075 10,352 Government grants 91,951 - Tax provisions 11 150 Other provisions 903 762 Contract liabilities 299,583 93,583 Other liabilities 28,061 7,490 Total current liabilities EUR 606,014 EUR 138,142 -------------------------------------- ------------- ------------ Total liabilities EUR 946,774 EUR 304,155
(MORE TO FOLLOW) Dow Jones Newswires
March 30, 2021 06:30 ET (10:30 GMT)
